Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 5Adenocarcinoma of Lung 3Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Salivary Gland Neoplasms 1Recurrent Squamous Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Multiple Myeloma 1MET Positive 1Lymphoma, Non-Hodgkin 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

Doxorubicin 7Ifosfamide 6brostallicin 2Trabectedin 2Filgrastim 2perifosine 1pegfilgrastim 1lorvotuzumab mertansine 1indolepropanol phosphate 1exatecan 1X-Rays 1Watchful Waiting 1Radiotherapy, Conformal 1Radiotherapy 1Observation 1Mass Spectrometry 1Imatinib Mesylate 1Erlotinib Hydrochloride 1Combined Modality Therapy 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Biopsy 1BI 2536 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neurofibrosarcoma × Erlotinib Hydrochloride × Clear all
NCT00068367 2017-11-06

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor

SWOG Cancer Research Network

Phase 2 Completed
24 enrolled 7 charts
Sarcoma

Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡